Pascal Touchon

Company: Atara Biotherapeutics

Job title: President & Chief Executive Officer

Seminars:

Allogeneic vs Autologous Cell Therapies: CAR-T & Beyond 10:00 am

How allogeneic T-cell therapies overcome limitations associated with autologous approaches available today Potential benefits of allogeneic EBV T-cells to address medical need in EBV driven cancers and auto-immune diseases as well as a platform for allogeneic CAR-T providing safety and efficacy with no need for gene editing TCR or HLARead more

day: Focus Day - Track A - Morning